[WEBINAR RECORDING] Planning a Successful MSC Therapy for Rapid COVID Response

Scaling Production and Managing Risks

Mesenchymal stromal/stem cells (MSCs) are in the forefront of cell therapies for COVID-19 treatment. However, the current COVID-19 pandemic requires rapid deployment of resources that can provide immediate access to MSC based therapeutics.

This webinar will cover challenges and options available for cell therapy product developers in scaling production, including industry best practices that will deliver rapid, safe, and cost-effective solutions to meet this crisis demand.

What you will learn:

true-sign Current state of MSC therapies for COVID-19: on-going trials and clinical evidence from ARDS experience

true-sign Current limitations and development of technology platforms to support future MSC manufacturing needs

true-sign Considerations in manufacturing readiness to support cGMP manufacturing of MSCs

Speakers

Mayasari Lim, Ph.D. – Moderator

Dr. Lim is a stem cell bioprocessing veteran with many years of experience developing bioreactor processes and application of experimental design strategies. She is active contributor in the bioprinting community and was recognized for her initiative in developing bioprinting tools for education as founder of SE3D. Prior to that, she was an Assistant Professor in Bioengineering at Nanyang Technological University in Singapore spearheading the stem cell bioprocessing group in bone marrow and cardiac tissue engineering. Dr. Lim obtained her PhD in Chemical Engineering from Imperial College London and BSc in Chemical Engineering from University of California, Berkeley. Dr. Lim currently supports the West Coast and APAC accounts for RoosterBio.

Timothy Olsen, Ph.D. – Speaker

TimOlsen_profile_photo

Dr. Olsen has over 8 years of experience in the regenerative medicine field with 15 publications. He earned a Bachelor’s in Biomedical Engineering from The College of New Jersey, a Master’s degree in Bioengineering from Clemson University, and a Ph.D. in Bioengineering from Clemson University. After his graduate studies, Dr. Olsen directed laboratory operations at Allevi and was a Bioink Engineer at the 3D bioprinting company. His next role was Senior Scientist on the Process and Product Development Team at RoosterBio, a regenerative medicine company focused on fueling the rapid commercialization of scalable human mesenchymal stem cell (MSC) technologies towards regenerative cures. His research experiences include MSC isolation, 2D culture process optimization, MSC media formulation development, 3D microcarrier-based bioreactor process development, and scaling up MSC manufacturing towards clinically and commercially relevant-lot sizes. Most recently, Dr. Olsen transitioned to the Commercial Team and is the Northeast USA and Europe Account Manager at RoosterBio.

[Webinar Recording] Planning a Successful MSC Therapy for Rapid COVID Response

Scaling Production and Managing Risks

What you will learn:

Submit Form below to View Recording!

Speakers